
    
      This is a multicenter, randomized, double-blind, parallel-group study. Subjects who meet the
      eligibility criteria at screening and meet the randomization criteria at the end of a 4 week
      run-in period will enter a 12 week treatment period. There will be a 7 day follow-up period
      after the treatment period.
    
  